Back to results
US 2024/0197880 A1Published application
New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapy
OwnerBeatriz ARANDA-ORGILLES, Tomasz KURCON +1inventors
InventorsBeatriz ARANDA-ORGILLES, Tomasz KURCON, Laurent POIROT
Life of this patent
Estimating the term…
Abstract
The present invention relates to genetically engineered immune cells expressing new anti-MUC1 chimeric antigen receptors and their use in the treatment of solid tumors, particularly suited for allogeneic cell immunotherapy.
Claims21
1-77. (canceled)
A method for manufacturing a population of engineered therapeutic immune cells, comprising the steps of:
- a) providing immune cells originating from a patient or donor;
- b) expressing in said cells an anti-MUC1 chimeric antigen receptor (CAR);
- c) introducing at least one genetic modification(s) in the genome of said cell, said modification(s) being selected from those leading to an enhanced IL-2, IL-12, IL-15 or IL-18 expression;
- d) expanding said cells to form a population of therapeutically effective immune cells.
1 more element
An engineered immune cell expressing an anti-MUC1 CAR, wherein said anti-MUC1 CAR comprises at least:
- an extracellular ligand binding-domain comprising VH and VL from a monoclonal antibody targeting tMUC1 epitope(s);
- a transmembrane domain;
- and
- a cytoplasmic domain comprising a CD3 zeta signalling domain and a co-stimulatory domain,
- wherein said extra cellular ligand binding-domain is directed against an antigen of the MUC1 polypeptide region HGVTSAPDTRPAPGSTAPPA (SEQ ID NO:1), and
- wherein said CAR is co-expressed with another exogenous sequence encoding a cytokine selected from IL-2, IL-12, IL-15 and IL-18.
3 more elements
Dependencies are inferred from the claim text.